Pirfenex contain pirfenidon as an active ingredient.
Pirfenex is orally active small molecule drugs that may inhibit collagen synthesis, down regulate production of multiple cytokines and block fibroblast proliferation and stimulation in response to cytokines.
Pirfenex has demonstrated activity in multiple fibrotic conditions, including those of the lung, kidney and liver.
It is being investigated by intermune.
Mode of action
Pirfenex is an orally active, small molecule that shows a wide range of biologic activity.
In vitro evidence has shown that Pirfenex inhibits collagen synthesis, down-regulates profibrotic cytokines and decreases fibroblast proliferation.
Pirfenex leads to a reduction of tgf-beta2 mRNA levels and of the mature tgf-beta2 protein due to decreased expression and direct inhibition of the tgf-beta pro-protein convertase furin.
Plasma concentration for this drug should be achieved after repeated doses of 200mg, 400mg and 600mg.
Pirfenex bind to human plasma protein, primarily to serum albumin single oral dosing of pirfinidon 100mg/kg.
Pirfenex is metabolized via cyp1a2 with other cyp isoenzymes including cyp2c9.
Pirfenex is indicated for the treatment of idiopathic pulmonary fibrosis.
Dosage and administration:
The initial dose for adult is 200mg.
Three times in a day, after meal.
Gradually increase the dose to 800mg. Three times in a day.
Start with 200mg three times in a day, after 2 week gradually increases the dose by 200mg to 800mg, three times in a day.
- Upper respiratory tract infection
- Weight decreased
- Hot flush
Inadequate information available. Multiple dose of Pirfenex up to dose 4806 mg per day were administered as six 267 mg capsule three times in a day.
Storage and handling:
Store in cool dry place.